Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome

Inclusion Criteria: * Molecular diagnosis of NALP3 mutations and clinical picture resembling Muckle-Wells Syndrome. * Muckle-Wells Syndrome patients who participated in the CACZ885A2102 study, will have the option to participate in this study upon disease flare * Muckle-Wells Syndrome patients requiring medical intervention either untreated or treated (i.e. under ACZ885, anakinra, or any other investigational IL-1 blocking therapy). Exclusion Criteria: * History of being immunocompromised, including a positive HIV at screening test result. * No live vaccinations within 3 months prior to the start of the trial, during the trial, and up to 3 months following the last dose. * History of significant medical conditions, which in the Investigator's opinion would exclude the patient from participating in this trial. * History of recurrent and/or evidence of active bacterial, fungal, or viral infections. * Positive tuberculin skin test at 48 to 72 hours after administration at the screening visit or within 2 months prior to the screening visit, according to national guidelines. Other protocol-defined inclusion/exclusion criteria may apply